Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $482,000.

  • Legend Biotech's Other Non Operating Income rose 201.25% to $482,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$162.0 million, marking a year-over-year decrease of 459.03%. This contributed to the annual value of $9.2 million for FY2022, which is 88.19% up from last year.
  • Latest data reveals that Legend Biotech reported Other Non Operating Income of $482,000 as of Q3 2025, which was up 100.45% from -$108.1 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Other Non Operating Income ranged from a high of $49.7 million in Q1 2024 and a low of -$108.1 million during Q2 2025.
  • For the 3-year period, Legend Biotech's Other Non Operating Income averaged around -$12.2 million, with its median value being $160,000 (2024).
  • As far as peak fluctuations go, Legend Biotech's Other Non Operating Income soared by 769.28% in 2022, and later plummeted by 6,093.50% in 2023.
  • Quarterly analysis of 5 years shows Legend Biotech's Other Non Operating Income stood at $2.1 million in 2021, then plummeted by 107.61% to -$163,000 in 2022, then tumbled by 6,093.50% to -$17.2 million in 2023, then surged by 100.93% to $160,000 in 2024, then spiked by 201.25% to $482,000 in 2025.
  • Its last three reported values are $482,000 in Q3 2025, -$108.1 million for Q2 2025, and -$54.5 million during Q1 2025.